Semaglutide
SimSon already publishes 180 observed catalogue products for Semaglutide while an Orange Book patent expiry falls due 16 February 2041 — on current evidence this is a WATCH, not yet a commercial move.Source
- DEPTH
- SimSon demonstrates substantial observed public catalogue depth for the molecule.
- Here: SimSon publicly lists 180 products for this API family (threshold 20).
- ADJACENCY
- SimSon has strong adjacent coverage and a small extension would complete an attractive family.
- Here: SimSon's own published impurity series omits 14, 15, 18, 19, 23, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 40, 41, 42; the gap is visible on SimSon's page.
Do nothing yet; re-check when the evidence changes.
Keep semaglutide under observation — the evidence does not yet support committing effort.
First step: Re-run the investigation when the catalyst approaches, or when SimSon's coverage changes.
See what is missing- Urgency
- Prepare ahead
- The catalyst is 173 months away, on 2041-02-16.
- Owner
- Not set
- Owner is not set: the system has no access to SimSon's org chart and will not guess one.
- Value — not public
- Cannot be established
- Revenue and margin are not public. This ranks the strength of the public signal, not the size of the prize — see what internal data would settle it.
Why now
Why SimSon
Observed from SimSon’s own public catalogue pages. This measures published coverage, not inventory, and it is not a statement that SimSon can synthesise any specific compound.
SimSon demonstrates adjacent public catalogue coverage: 180 products observed on its own semaglutide API page and 5 isotope-labelled products. This is capability evidence; it is not a statement that SimSon can synthesise any specific compound.Source
- Total products
- 180
- Isotope-labelled
- 5
- Peptide-related
- 180
SimSon publishes a numbered impurity series for this API with 14, 15, 18, 19, 23, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 40, 41, 42 absent between published neighbours.
A checkable fact about SimSon’s published page, not an inference.
isotope labelled · impurity standards · peptide
Organisations publicly associated with this molecule
No public filing record names an organisation for semaglutide in the current evidence set, so no buyer-candidate is asserted.
How this decision was reached
R6B_DISTANT_LOEThe only dated catalyst is a loss of exclusivity beyond the 24-month action horizon.
Loss of exclusivity is 173 months away — beyond the 24-month action horizon.
This is a system recommendation, not system evidence. It was selected by a fixed rule evaluated top to bottom over the values above — no model, no judgement. Change the inputs and the rule changes with them.
WATCH — rule R6B_DISTANT_LOE. Loss of exclusivity is 173 months away — beyond the 24-month action horizon.
Opportunity score
- Market activity
- 16.1
- Regulatory catalyst
- 12.0
- Competitor scarcity
- Not scored
- Capability adjacency
- 85.0
- Evidence quality
- 70.0
Why competitor scarcity is not scored
Identity-grade competitor coverage was insufficient across the three suppliers this dimension requires. The 20 weight points it would have carried were removed from the denominator rather than scored as zero, so the remaining dimensions keep their relative influence.
- Daicel Chiral Technologies India Pvt. Ltd.NOT CHECKED — unresolved candidate products remain
1 candidate product(s) could not be resolved at identity grade.
- Veeprho Laboratories Pvt. Ltd.NOT CHECKED — publisher restricts automated retrieval
robots.txt returned HTTP 403 — treating host as disallowed
A false competitive gap is materially worse than a missing scarcity score, so the dimension stays unscored until the evidence standard is met.
- Distinct ANDA sponsors
- 0
- Marketed products
- 6
- Distinct trial sponsors
- Not checked
ClinicalTrials.gov disallows our agent on /api/ in its robots.txt. The trial component was omitted from the weighted average rather than scored zero, and no substitute source was used.
Evidence ledger
- Retrieval datePrimaryLive retrievalU.S. Food and Drug AdministrationFDA Orange Book data filesobserved
Orange Book patent row
N 209637 product 007
https://www.fda.gov/media/76860/download?attachmentRetrieved 13 SEPT 2026
- Retrieval datePrimaryLive retrievalSimSon Pharma LimitedSimSon public catalogueobserved
SimSon catalogue coverage — semaglutide
180 products observed on https://www.simsonpharma.com/products/Semaglutide
https://www.simsonpharma.com/products/SemaglutideRetrieved 13 SEPT 2026
What internal SimSon data would change this decision?
Everything above was built from information anyone can retrieve. The scoring is deterministic and the evidence is cited — but each of the following would sharpen this recommendation materially, and none of it is public.
Realised selling price and margin per catalogue item
Every opportunity here is ranked by signal strength, never by profit. A high-scoring molecule may be one SimSon sells at its thinnest margin.
Would be resolved by: SimSon price book and cost model
Actual competitor pricing, stock and terms
Public catalogues show listings, never terms. Even where a competitor listing is observed, it says nothing about price or availability.
Would be resolved by: Not public — sales intelligence or direct enquiry
competitor scarcity is NOT SCORED (0 of the 3 required suppliers hold an identity-grade verdict); the ClinicalTrials.gov trial-sponsor component is omitted from market activity because that publisher's robots.txt disallows our agent on /api/ — omitted, not scored zero; catalogue depth is capability evidence only and carries no demand claim.Source